{"DataElement":{"publicId":"5456180","version":"1","preferredName":"Person Receive Systemic Corticosteroid Therapy Prior To Protocol Agent Pharmacologic Substance Administration Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A response to determine eligibility for clinical trial participation for questions related to the patient's receipt of treatment with corticosteroids prior to the act of the dispensing, applying, or tendering a substance that is tested in a clinical trial.","longName":"CRSTD_TX_PRR_STDYAGT_ADMN_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5456141","version":"1","preferredName":"Person Receive Systemic Corticosteroid Therapy Prior To Protocol Agent Pharmacologic Substance Administration Clinical Trial Eligibility Criteria","preferredDefinition":"A human being._To take, accept, or get something offered._Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous)._Earlier in time or order._Used as a function word to indicate direction, purpose, or movement._A medical product, practice, or application that is tested in a clinical trial._Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2236731v1.0:5456139v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5456139","version":"1","preferredName":"Receive Systemic Corticosteroid Therapy Prior To Protocol Agent Pharmacologic Substance Administration Clinical Trial Eligibility Criteria","preferredDefinition":"To take, accept, or get something offered.:Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).:Earlier in time or order.:Used as a function word to indicate direction, purpose, or movement.:A medical product, practice, or application that is tested in a clinical trial.:Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.:The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5456139v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Systemic Corticosteroid Therapy","conceptCode":"C122080","definition":"Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Protocol Agent","conceptCode":"C41161","definition":"A medical product, practice, or application that is tested in a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C15FD55-C38A-0D38-E050-BB89AD431F0D","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"ONEDATA","dateModified":"2016-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C15FD55-C39B-0D38-E050-BB89AD431F0D","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"TAYLORT","dateModified":"2016-09-20","changeDescription":"9/20/16 tt, approved/released. 9/9/16 tt, created for 9910.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Has patient been receiving sy","type":"Preferred Question Text","description":"Has patient been receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within 1 week before administration of the first dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has previously required corticosteroids for symptom control, have they been off steroids for at least 3 days without recurrence of symptoms prior to starting trial therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient been on any systemic corticosteroid therapy within 1 week before the planned date for the first dose on study?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Have corticosteroids been administered as antiemetics prior to copanlisib?","url":null,"context":"Theradex"},{"name":"CRG Text 1","type":"Alternate Question Text","description":"Corticosteroid dose > 10mg at time of registration?","url":null,"context":"NRG"},{"name":"CRF text2","type":"Alternate Question Text","description":"Has the patient required chronic suppressive steroid therapy within 7 days of study entry?","url":null,"context":"NRG"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Has the patient required immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers  within 7 days prior to study entry?","url":null,"context":"NRG"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Has the patient required chronic suppressive steroid therapy within 7 days of study entry(greater than the equivalent of 20mg/day of prednisone, methotrexate, azathioprine and TNF-α  blockers)?","url":null,"context":"NRG"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C162112-C94A-827D-E050-BB89AD435030","latestVersionIndicator":"Yes","beginDate":"2016-09-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2016-09-09","modifiedBy":"BERGANTW","dateModified":"2020-03-20","changeDescription":"9/20/16 tt, approved/released. 9/9/16 tt, created for 991.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}